Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$193.33 - $291.99 $1.88 Million - $2.83 Million
-9,700 Reduced 11.83%
72,300 $20.3 Million
Q1 2024

May 15, 2024

BUY
$171.37 - $283.23 $5.36 Million - $8.87 Million
31,300 Added 61.74%
82,000 $21.9 Million
Q4 2023

Feb 14, 2024

BUY
$120.4 - $237.13 $1.37 Million - $2.7 Million
11,400 Added 29.01%
50,700 $11.7 Million
Q3 2023

Nov 14, 2023

SELL
$146.04 - $225.78 $1.78 Million - $2.75 Million
-12,200 Reduced 23.69%
39,300 $5.74 Million
Q2 2023

Aug 14, 2023

SELL
$203.88 - $312.0 $5.5 Million - $8.42 Million
-27,000 Reduced 34.39%
51,500 $11.9 Million
Q1 2023

May 15, 2023

SELL
$231.06 - $307.08 $21 Million - $27.9 Million
-90,700 Reduced 53.61%
78,500 $19 Million
Q4 2022

Feb 14, 2023

BUY
$58.39 - $296.54 $7.99 Million - $40.6 Million
136,900 Added 423.84%
169,200 $49.1 Million
Q3 2022

Nov 14, 2022

SELL
$60.57 - $79.51 $175,653 - $230,579
-2,900 Reduced 8.24%
32,300 $2.1 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $3.99B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.